Literature DB >> 3734034

Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome.

X Bertagna, C Bertagna, M H Laudat, J M Husson, F Girard, J P Luton.   

Abstract

RU 486 [17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)17 alpha-(prop-1-ynyl)estra-4,9-dien-3-one] is a steroid analog which antagonizes glucocorticoid action at the receptor level. The pituitary-adrenal response to RU 486 was evaluated in patients with Cushing's syndrome. The acute administration of 400 mg RU 486 at 0800 h in five patients with Cushing's disease induced no significant change in plasma cortisol during the next 10 h compared with the administration of placebo. However, prolonged administration (400 mg daily for 3 days) caused activation of the pituitary-adrenal axis; urinary cortisol increased the most from 727 to 5720, 830 to 8200, 610 to 1020, 110 to 570, and 300 to 990 micrograms/day. Plasma cortisol and lipotropins increased to a lesser extent. Hormone changes appeared on the second day of drug administration and lasted up to 3-4 days after the drug was discontinued. In two patients with nonpituitary-dependent Cushing's syndrome, RU 486 induced no significant change in steroid secretion. We conclude that RU 486 induced a delayed and prolonged pituitary-adrenal response in Cushing's disease; whether the resulting cortisol overproduction will overcome the peripheral effect of RU 486 remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3734034     DOI: 10.1210/jcem-63-3-639

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

Review 1.  Medical termination of pregnancy.

Authors:  J Guillebaud
Journal:  BMJ       Date:  1990 Aug 18-25

2.  Clinical pharmacokinetics of mifepristone.

Authors:  O Heikinheimo
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

3.  Diagnosis and treatment of Cushing's syndrome. Cushing's syndrome: current clinical problems, symposium. Padova, October 19-20, 1990.

Authors: 
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

Review 4.  Novel medical approaches for the treatment of Cushing's disease.

Authors:  A P Heaney
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 5.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

6.  Adrenocorticotropin responsiveness to acute octreotide administration is not affected by mifepristone premedication in patients with Cushing's disease.

Authors:  Francesco Ferrau; Francesco Trimarchi; Salvatore Cannavo
Journal:  Endocrine       Date:  2014-01-10       Impact factor: 3.633

Review 7.  Glucocorticoid-induced hypertension.

Authors:  Julie E Goodwin; David S Geller
Journal:  Pediatr Nephrol       Date:  2011-07-09       Impact factor: 3.714

8.  Treatment of severe psychosis due to ectopic Cushing's syndrome.

Authors:  Y M Bilgin; H E van der Wiel; H R Fischer; W W De Herder
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

Review 9.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

Review 10.  Novel pituitary ligands: peroxisome proliferator activating receptor-gamma.

Authors:  Anthony P Heaney
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.